NasdaqGS:TERNPharmaceuticals
Terns Pharmaceuticals (TERN) Is Down 7.7% After Strong TERN-701 Phase 1 Data - Has The Bull Case Changed?
Earlier in December, Terns Pharmaceuticals reported positive Phase 1 results for its chronic myeloid leukemia candidate TERN-701, including a 64% major molecular response rate and a 75% response rate at doses of 320 mg and above over 24 weeks, supporting advancement into Phase 2 trials.
This progress underscores how TERN-701 is emerging as a central pillar of Terns’ pipeline, potentially reshaping the company’s future clinical focus.
We will now examine how the encouraging TERN-701 Phase 1...